A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body - Trial NCT06393127
Access comprehensive clinical trial information for NCT06393127 through Pure Global AI's free database. This Phase 1 trial is sponsored by Boehringer Ingelheim and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 64 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Boehringer Ingelheim
Timeline & Enrollment
Phase 1
May 07, 2024
Aug 30, 2024
Primary Outcome
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz),Maximum measured concentration of the analyte in plasma (Cmax)
Summary
The main objective of this trial is to establish the bioequivalence of the BI 1015550
 Formulation C2 (Test, T) and the BI 1015550 Formulation C1 (Reference, R), following a single
 oral dose administration.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06393127
Non-Device Trial